Repligen completes purchase of BioLife Solutions
Repligen Corporation announced that it has finalized its acquisition of BioLife Solutions on October 6, 2026. BioLife shareholders were paid $11.25 in cash for each share and received 0.1442 shares of Repligen common stock. The deal adds BioLife’s cell‑processing consumables and biopreservation media, which support 18 approved therapies, to Repligen’s bioprocessing portfolio. Repligen said it will detail the transaction’s effect on its 2026 outlook during its upcoming third‑quarter earnings call.
Why it matters
The company indicated that the acquisition will broaden its presence in the fast‑growing cell‑therapy market and generate recurring, high‑margin revenue, which could improve its financial performance once integration is complete. Repligen will discuss the expected impact on its 2026 guidance at the Q3 earnings call, giving investors insight into future earnings.
Key facts
- 1The acquisition was completed on October 6, 2026. globenewswire.com
- 2BioLife shareholders received $11.25 in cash per share and 0.1442 shares of Repligen common stock for each BioLife share. globenewswire.com
- 3BioLife’s biopreservation media portfolio supports 18 commercially approved therapies and most U.S. cell‑based therapy trials. globenewswire.com
- 4Perella Weinberg Partners and Goldman Sachs acted as financial advisors to Repligen; Centerview Partners advised BioLife. globenewswire.com
- 5Repligen will provide additional detail on the transaction’s impact on its 2026 financial outlook during its third‑quarter earnings call. globenewswire.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.